Pharmaceutical Technology

OCTOBER 26, 2023

Tocilizumab biosimilar is under clinical development by Fresenius Kabi SwissBioSim and currently in Pre-Registration for Rheumatoid Arthritis.

40

40

Pharmaceutical Technology

FEBRUARY 22, 2023

Tocilizumab biosimilar is under clinical development by Bio-Thera Solutions and currently in Pre-Registration for Rheumatoid Arthritis.

52

52

The Checkup by Singlecare

OCTOBER 3, 2023

Aspirin is useful in osteoarthritis , rheumatoid arthritis , joint pain, and other pain-related disorders. Tylenol is not an anti-inflammatory drug, but it does have some analgesic properties and can be useful for some pain types, such as arthritis and headaches. It can also treat or prevent angina pectoris or chest pain.

Dosage 98

Dosage Insurance 98

BuzzRx

SEPTEMBER 6, 2022

Rheumatoid arthritis (RA) is an inflammatory autoimmune disease in which the body’s immune system mistakenly attacks the lining of the joints (the synovium), causing pain and inflammation, which leads to joint damage over time. There is no cure for rheumatoid arthritis. DMARDs also prevent joint damage.

Immunization 52

Immunization Vaccines 52

STAT

OCTOBER 4, 2023

The Center charges that these tests are not nearly as accurate as their maker claims they are, and that they aren’t good at distinguishing between fibromyalgia and other diseases with similar symptoms such as rheumatoid arthritis and lupus. The suit cites a STAT investigation of EpicGenetics published in October 2021.

Insurance 126

Insurance Hospitals 126

The Checkup by Singlecare

DECEMBER 15, 2022

Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis , psoriatic arthritis, and ankylosing spondylitis are all autoimmune diseases, and they stem from an immune system malfunction, which causes our immune cells to attack body parts such as bowel, joints, and skin. Remicade coupons. Renflexis (infliximab).

Immunization 52

Immunization Dosage Labelling FDA 52

Med Ed 101

JULY 31, 2022

The most common use in clinical practice that I’ve seen sulfasalazine used for is rheumatoid arthritis, but it can also play a role in ulcerative colitis and Crohn’s disease. In this post, I’ll discuss important sulfasalazine clinical pearls and […].

45

45

European Pharmaceutical Review

APRIL 3, 2023

It relies partly on results of pre-clinical tests and clinical trials of an already authorised reference product and in part on new data. This condition is a persistent swelling which does not respond to diuretics and sodium restriction. This medicine was submitted as a hybrid application.

Vaccines 88

Vaccines Chemotherapy Generic Medicine 88

pharmaphorum

OCTOBER 12, 2021

Usually used to treat rheumatoid arthritis, Actemra was granted emergency approval in June for hospitalised patients 2 years of age and older who are receiving systemic corticosteroids and need respiratory support after it was shown to reduce mortality in a clinical trial.

Labelling 105

Labelling 105

Hospital Pharmacy Europe

AUGUST 22, 2023

An anti-IL17 peptide sequence has demonstrated high clinical efficacy in models of immune-mediated inflammatory conditions, warranting further clinical evaluation. However, these novel agents often show low therapeutic efficacy and immunogenicity in certain patient subgroups, thereby limiting their effectiveness.

Immunization 52

Immunization Hospitals 52

Pharmaceutical Technology

MARCH 2, 2023

Rituximab biosimilar is under clinical development by Dr. Reddy’s Laboratories and currently in Phase III for Rheumatoid Arthritis. According to GlobalData, Phase III drugs for Rheumatoid Arthritis have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration.

Pharmaceutical Companies 40

Pharmaceutical Companies Pharmaceutical Companies 40

pharmaphorum

DECEMBER 15, 2021

Bristol-Myers Squibb’s rheumatoid arthritis drug Orencia has been approved by the FDA to prevent graft versus host disease (GvHD), a serious complication of haematopoietic stem cell transplant (HSCT) used to treat leukaemias and other blood cancers. billion in the first nine months of the year.

FDA 105

FDA Immunization 105

European Pharmaceutical Review

NOVEMBER 1, 2022

The proposed restrictions are due to a review of available data, including clinical trial results for Xeljanz and initial findings from an observational study of Olumiant. The PRAC has confirmed that individuals with the following chronic inflammatory disorders should not take JAK inhibitors: Rheumatoid arthritis (RA).

92

92

European Pharmaceutical Review

DECEMBER 7, 2023

A world-first clinical trial in type 1 diabetes In the Phase II clinical trial for baricitinib, investigators monitored the blood glucose and insulin production of 91 participants aged between 10 and 30 years old, over a one-year period. 

Immunization 107

Immunization 107

The Checkup by Singlecare

OCTOBER 25, 2023

Meloxicam reduces pain, tenderness, swelling, and stiffness caused by conditions like rheumatoid arthritis , osteoarthritis , ankylosing spondylitis , and juvenile rheumatoid arthritis. RELATED: Osteoarthritis vs. rheumatoid arthritis : Which one do I have? Many of these conditions are painful and chronic.

Mayo Clinic 105

Mayo Clinic Controlled Substances Dosage Compounding 105

European Pharmaceutical Review

JANUARY 4, 2023

EVOQ Therapeutics Inc has agreed to license its NanoDisc technology for rheumatoid arthritis (RA) and lupus to Gilead Sciences, Inc, enabling EVOQ to potentially receive up $658.5 The companies will collaborate to advance preclinical development and Gilead will be responsible for clinical development and commercialisation.

Immunization 52

Immunization 52

Hospital Pharmacy Europe

FEBRUARY 18, 2023

Moreover, a feature of autoimmune diseases such as rheumatoid arthritis is inflammation and it was shown in one meta-analysis that there was a 29% higher risk of AF among those with rheumatoid arthritis. Despite this, the link between AF and other autoimmune disorders is less clear. Citation Tilly MJ et al.

Hospitals 52

Hospitals 52

Pharmaceutical Technology

MAY 25, 2023

Yuflyma is indicated to treat juvenile idiopathic arthritis, hidradenitis suppurativa, Crohn’s disease, plaque psoriasis, ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis and ulcerative colitis.

FDA 52

FDA Packaging Patient Care 52

European Pharmaceutical Review

MAY 18, 2023

The NICE recommendation is based on data from three Phase III clinical trials, which demonstrated significantly more patients treated with upadacitinib achieved the co-primary endpoints of clinical remission and endoscopic response.

Immunization 87

Immunization Hospitals 87

Pharmaceutical Technology

MARCH 1, 2023

It has also been approved in several countries for treating moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have not responded to or tolerated previous therapy. Developed using VelocImmune technology of Regeneron, Kevzara binds to the IL-6 receptor specifically and inhibits IL-6-mediated signalling.

FDA 98

FDA Adverse Reactions 98

European Pharmaceutical Review

NOVEMBER 22, 2022

a China-based pharma company has announced it has received clearance for its Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to initiate clinical studies of T21, a 3D-printed medicine that can target specific segments in the colon to more safely deliver oral ulcerative colitis (UC) drugs.

Dosage 108

Dosage FDA 108

The People's Pharmacy

MAY 8, 2023

Structural chemical formulas of corticosteroids (glucocorticoids): cortisol, cortisone, corticosterone A Quick Overview of Cortisone: A patient with rheumatoid arthritis first received cortisone just over 70 years ago. Cortisone was hailed as a miracle cure for rheumatoid arthritis. Cortisone Shots: A Risky Tradeoff?

Hospitals 102

Hospitals FDA 102

Pharmaceutical Technology

FEBRUARY 19, 2023

Annexuzlimab is under clinical development by MedAnnex and currently in Phase I for Kidney Cancer (Renal Cell Cancer). Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. It also provides non-clinical testing programs.

40

40

PharmaShots

APRIL 28, 2023

Shots: Eli Lilly has licensed ZB-106 (Tibulizumab) to Zura, and in exchange, Zura will pay Eli Lilly $4.25 million in Class A Ordinary Shares as part of the upfront cash payment Zura has also reported its agreement to sell ~18.8M Class A ordinary shares at $4.25

40

40

PharmaShots

APRIL 28, 2023

In Aug 2022, the company received IND clearance from the USFDA to initiate the P-I clinical trial of DWP213388. Also, Vitalli Bio will be granted an option to license earlier-stage dual-target inhibitors in development by Daewoong DWP213388, a BTK and ITK inhibitor.

40

40

PharmaShots

MAY 4, 2023

rheumatoid arthritis The primary outcome measures will be to show the comparative efficacy of AVT05 vs Simponi @16wks. based on change from baseline on a standardized DAS28-CRP which evaluates the severity of RA using clinical and laboratory data Additionally, the company initiates PK study for AVT05 in Jan 2023.

40

40

Pharmaceutical Technology

NOVEMBER 1, 2022

These drugs could potentially treat GBA and some inflammatory ailments, including irritable bowel syndrome, inflammatory bowel diseases, rheumatoid arthritis, atopic dermatitis, oligoarticular juvenile idiopathic arthritis and autism spectrum disorder.

Compounding 59

Compounding 59

BuzzRx

SEPTEMBER 6, 2022

To demonstrate, the biologic drug Humira (generic name adalimumab), which is used to treat autoimmune diseases like rheumatoid arthritis and Crohn’s disease , costs over $6,000 for 1 carton (2 pens) without insurance. What are biologics for rheumatoid arthritis? But these drugs are also some of the most expensive.

Insurance Coverage 52

Insurance Coverage Immunization Insurance Pharmaceutical Companies 52

Hospital Pharmacy Europe

FEBRUARY 16, 2023

His interest in psoriatic arthritis (PsA) arose after working alongside a dermatology department in Seattle where he treated many patients referred by dermatologists for the treatment of their arthritic component. His work on PsA took off after undertaking a clinical trial with etanercept in 2000. What is PsA and how common is it?

Immunization 52

Immunization Hospitals Documentation FDA 52

European Pharmaceutical Review

MARCH 4, 2024

This growth is accompanied by a substantial number of clinical trials, with close to 20,000 active investigations, involving about 9,500 new biologic treatments. Despite issues of potential toxicity and biocompatibility, several polymers have advanced to clinical trial stages. percent through 2027.

FDA 93

FDA Vaccines Immunization Compounding 93

PharmaShots

JUNE 27, 2023

Food and Drug Administration (FDA) have accepted the Marketing Authorization Application and the abbreviated Biologics License Application (aBLA), respectively, for BIIB800 in Q4 2022 with the Phase 3 trial being conducted in rheumatoid arthritis (RA) patients. Smriti: Can we talk about BIIB800, a tocilizumab biosimilar?

Immunization 40

Immunization FDA 40

The Checkup by Singlecare

MARCH 22, 2024

According to Cleveland Clinic , eczema is common and affects 31 million people in the United States. It can also be used to treat severe rheumatoid arthritis (RA) or severe psoriasis. It can also be used to treat adults with other conditions, such as rheumatoid arthritis , Crohn’s disease , and ulcerative colitis.

Immunization 105

Immunization FDA Packaging Labelling 105

pharmaphorum

DECEMBER 6, 2021

Therefore extensive consideration of the clinical and cost-effectiveness of treatments must be made, to justify their value for money and their value to the health system. The combination treatment issue. The post How the combination treatment challenge impacts patients and how we are working together to solve it appeared first on.

52

52

European Pharmaceutical Review

SEPTEMBER 20, 2022

Over the past 15 years and the experience from clinical practice has shown that in terms of efficacy, safety and immunogenicity they are comparable to their reference products and are therefore interchangeable,” commented EMA’s Executive Director, Emer Cooke.

94

94

Pharmaceutical Technology

MARCH 21, 2023

Gilead Sciences has exercised its option to exclusively license the investigational targeted protein degrader development candidate, NX‑0479, from clinical-stage biopharmaceutical company Nurix Therapeutics. The company stated that the degradation of IRAK4 can help treat rheumatoid arthritis (RA), as well as other inflammatory diseases.

52

52

pharmaphorum

JANUARY 15, 2021

Join the world’s top ILD specialists as they guide you through the seminal research and insights you need to confidently define, understand, and develop clinically effective antifibrotic therapies against connective tissue disease, rheumatoid arthritis, hypersensitivity pneumonitis, Goodpasture’s syndrome, and much more.

52

52

Pharmaceutical Technology

FEBRUARY 25, 2023

ASP-1570 is under clinical development by Astellas Pharma and currently in Phase II for Metastatic Melanoma. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

52

52